See Recent Shionogi-Sponsored Congress Presentations

Congresses

As part of our commitment to addressing unmet medical needs, Shionogi continues to investigate approved products and pipeline compounds. Shionogi presents its research at major congress events globally.

The content contained herein is for your information only. No reproduction, alteration, or distribution of this information is permitted. Information about investigational compounds or investigational uses of products does not imply FDA approval of these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the investigational compounds or investigational uses will receive FDA approval. Shionogi does not recommend or suggest use of its products in a manner inconsistent with FDA-approved labeling.

Select a congress event or filter to view available congress presentations.

You Are Viewing Presentations

IDWeek 2025
Ensitrelvir

Clearance of infectious virus in COVID-19 patients treated with ensitrelvir across vaccination status, age, and risk subgroups: exploratory analyses from the SCORPIO-HR study

IDWeek 2025
Cefiderocol

Clinical outcomes of cefiderocol for treatment of bloodstream infections caused by gram-negative bacteria: subgroup analysis of the PROVE study

ASM Microbe 2025
Cefiderocol

Comparison of conventional and iron-depleted agar plates for susceptibility testing of cefiderocol by disk diffusion

IDWeek 2024
Cefiderocol

Correlation analysis of cefiderocol in vitro activity and in vivo efficacy against Acinetobacter baumannii strains with difficult-to-read MIC endpoints

GSA 2025
Ensitrelvir

COVID-19 exposure, treatment patterns, and healthcare utilization in US long-term care: retrospective EHR study

ASCP 2025
Ensitrelvir

Current impact of COVID-19 in long-term care facilities in the United States: systematic literature review 

You Are Viewing Congress Locations